Wanbury Limited ( (IN:WANBURY) ) has provided an update.
Wanbury Limited’s board meeting on February 12, 2025, resulted in key financial and strategic decisions. The company approved its unaudited financial results for the third quarter and nine months ending December 31, 2024. Additionally, Wanbury plans to issue non-convertible debentures amounting to Rs. 175 crore through private placement to Emerging India Credit Opportunities Fund II, aiming to strengthen its financial position. The board also approved the grant of 200,000 stock options to employees under the Wanbury ESOP 2016 plan, reflecting the company’s focus on incentivizing and retaining talent.
More about Wanbury Limited
Wanbury Limited operates in the pharmaceutical industry, providing a range of healthcare products and services. The company focuses on the development, manufacturing, and distribution of pharmaceutical formulations and bulk drugs, catering to both domestic and international markets.
YTD Price Performance: -27.70%
Average Trading Volume: 22,819
Current Market Cap: 7.55B INR
Find detailed analytics on WANBURY stock on TipRanks’ Stock Analysis page.